furazolidone has been researched along with Infections, Helicobacter in 128 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 9.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "To observe the effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory H." | 9.15 | [Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection]. ( Gao, W; Hu, FL; Wang, XM, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 9.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 9.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| " pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o." | 9.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "Seventy-two patients with Helicobacter pylori-associated chronic gastritis were randomized to a 3-week oral treatment with furazolidone 0." | 9.06 | The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. ( Jiang, SJ; Liu, WZ; Wang, RN; Xia, DH; Xiao, SD; Xu, WW; Zhang, ZH, 1990) |
| "The histamine concentration of the oxyntic mucosa was determined in Helicobacter pylori-positive patients with duodenal ulcer before and after antimicrobial therapy and in H." | 7.68 | Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication. ( Coelho, LG; Cunha-Melo, JR; Lima Júnior, GF; Mendes, EN; Moura, SB; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 5.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 5.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| "To observe the effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory H." | 5.15 | [Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection]. ( Gao, W; Hu, FL; Wang, XM, 2011) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 5.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 5.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| " pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o." | 5.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| "Seventy-two patients with Helicobacter pylori-associated chronic gastritis were randomized to a 3-week oral treatment with furazolidone 0." | 5.06 | The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. ( Jiang, SJ; Liu, WZ; Wang, RN; Xia, DH; Xiao, SD; Xu, WW; Zhang, ZH, 1990) |
| "The histamine concentration of the oxyntic mucosa was determined in Helicobacter pylori-positive patients with duodenal ulcer before and after antimicrobial therapy and in H." | 3.68 | Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication. ( Coelho, LG; Cunha-Melo, JR; Lima Júnior, GF; Mendes, EN; Moura, SB; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| " Helicobacter pylori status and the histology of the antral and oxyntic mucosa were evaluated in 25 patients with duodenal ulcer treated with a triple schedule of furazolidone, metronidazole and amoxicillin, and in 16 patients treated only with cimetidine." | 3.68 | Histology of the mucosa of gastric antrum and body before and after eradication of Helicobacter pylori. ( Barbosa, AJ; Castro, LP; Coelho, LG; Lima Júnior, GF; Mendes, EN; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| "Forty-eight patients with endoscopically proven duodenal ulcer (DU) and Helicobacter pylori infection detected by 14C-urea breath test (BT) were assigned to 5 days of treatment with furazolidone, metronidazole, and amoxicillin in addition to eventual classical anti-ulcer agents if necessary." | 3.68 | Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. ( Brandao, MJ; Castro, LP; Chausson, Y; Coelho, LG; Costa, EL; Maia, AF; Passos, MC; Rodrigues, DC, 1992) |
| " The secondary endpoints were adverse effects, symptom improvement rates, and patient compliance." | 3.11 | Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. ( Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X, 2022) |
| " Adverse events were recorded during follow-up by telephone interview." | 3.01 | Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. ( Cao, Y; He, W; Li, X; Wang, J, 2021) |
| "Furazolidone is a nitrofuran antimicrobial agent used in the treatment of bacterial and protozoal infections." | 3.01 | Delayed-type allergic reaction to furazolidone: A case report and review of the literature. ( Meng, J; Xiao, H; Xu, F; Zhang, H, 2023) |
| "We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients." | 2.82 | Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy. ( Bao, ZJ; Huang, YQ; Shi, DM; Xiang, P; Xiao, L; Yin, SM; Zhang, F; Zhang, GS, 2016) |
| "The use of this probiotic compound compared to placebo in the proposed regimen in Brazilian patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy or adverse effects." | 2.78 | Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. ( Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013) |
| " Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration." | 2.77 | A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. ( Bari, Z; Fakheri, H; Sardarian, H, 2012) |
| "Furazolidone has been effective against Helicobacter pylori in Iran, with no resistance, but with intolerable side effects in the second week." | 2.73 | Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. ( Agah, S; Ajvadi, Y; Ali-Asgari, A; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Nasseri-Moghaddam, S; Pourshams, A; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2007) |
| " Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes." | 2.73 | Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. ( Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008) |
| "Furazolidone has recently shown promising efficacy in H." | 2.71 | The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. ( Bahrami, H; Ebrahimi-Dariani, N; Haghpanah, B; Mansour-Ghanaei, F; Mirmomen, S; Noormohammadpoor, P; Sotodehmanesh, R, 2003) |
| "Furazolidone is a very good substitute for metronidazole and clarithromycin, but its many side-effects limit widespread use." | 2.71 | Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. ( Butorab, Z; Massarrat, S; Roghani, HS; Shirekhoda, M, 2003) |
| "pylori therapy in family members of gastric cancer patients." | 2.71 | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. ( Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS, 2003) |
| "A urea breath test was performed 1-2 months after eradication." | 2.71 | Eradication rate of Helicobacter pylori in dyspeptic patients. ( Amini, M; Khedmat, H; Yari, F, 2005) |
| "Duodenal ulcers were healed in nine of 10 (90%) patients in the BTF group and in all patients (12/12) (100%) in the OBTM group (P = N." | 2.70 | Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. ( Domareva, I; Ganskaya, Z; Isakov, V; Koudryavtseva, L; Maev, I, 2002) |
| " Short-term treatment with omeprazole did alter the relative bioavailability of this drug, probably through an effect on absorption kinetics or first-pass metabolism." | 2.70 | Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ( Calafatti, SA; Deguer, M; Martinez, M; Ortiz, RA; Pedrazzoli, J, 2001) |
| "Amoxicillin resistance was not found." | 2.70 | One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. ( Fung, FM; Gu, Q; Lai, KC; Lam, SK; Lu, H; Wang, WH; Wong, BC; Wong, WM; Xia, HH; Xiao, SD; Yin, Y, 2002) |
| "Rapid recurrence of H." | 2.68 | Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. ( Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J, 1997) |
| " Primary outcomes were the risk of total adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) with 95% CI." | 2.66 | Safety of furazolidone-containing regimen in ( Guo, CG; Ji, CR; Li, YY; Liu, J; Qu, JY; Zhang, Y; Zuo, X, 2020) |
| "Furazolidone-containing treatments could achieve satisfactory eradication rates and did not increase the incidence of total or severe adverse effects, but the incidence of milder side effects, such as fever and anorexia, should be considered when prescribing furazolidone-containing treatments to patients." | 2.58 | Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. ( Li, Z; Wang, Y; Wu, S; Xie, Y; Zhao, RL; Zhuge, L, 2018) |
| "furazolidone was 80% intention to treat (ITT) and 87% per protocol (PP)." | 2.55 | Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. ( Attaran, B; Graham, DY; Malekzadeh, R; Mohammadi, M, 2017) |
| "Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9." | 1.91 | [Effectiveness of empirical ( Abdulkhakov, RA; Abdulkhakov, SR; Alekseenko, SA; Andreev, DN; Bakanova, NV; Bakulin, IG; Bakulina, NV; Bogomolov, PO; Bordin, DS; Bueverova, EL; Gisbert, J; Kolbasnikov, SV; Kononova, AG; Livzan, MA; Maev, IV; Megraud, F; Moreira, L; O'Morain, C; Osipenko, MF; Perez Nyssen, O; Sarsenbaeva, AS; Starostin, BD; Tarasova, GN; Tarasova, LV; Voynovan, IN; Zaytsev, OV, 2023) |
| "Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial action and has been widely used in the treatment of Helicobacter pylori (H." | 1.72 | Risk factors of furazolidone-associated fever. ( Chen, J; Dai, H; Rong, C; Yan, C; Yang, W; Yu, L; Zhang, J, 2022) |
| "To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017." | 1.56 | Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication. ( Chen, J; Chen, Q; Fang, HM; Huang, YT; Kan, LD; Li, LC; Qiu, Y; Yu, XL, 2020) |
| " Adverse drug reactions occurred in 8." | 1.51 | Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. ( Ding, L; Lu, N; Qian, X; Shu, X; Song, C; Song, Y; Wang, H; Xie, Y; Xiong, Z; Ye, J; Yu, T; Zhu, Y, 2019) |
| " The patients should be watched closely during the treatment since the adverse effects of this regimen happen frequently." | 1.40 | [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study]. ( Cheng, H; Dong, X; Gao, W; Hu, F; Liu, X, 2014) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 1.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| "Amoxicillin resistance was 2." | 1.33 | Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. ( Doratotaj, D; Fallahi, GH; Khatami, GR; Mirnaseri, MM; Safari, F; Siavoshi, F, 2006) |
| "Furazolidone is an inexpensive antibiotic that has considerable anti-Helicobacter pylori activity in vitro." | 1.30 | Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. ( Kooy, A; Thijs, JC; van der Wouden, EJ; Van Zwet, AA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (13.28) | 18.2507 |
| 2000's | 50 (39.06) | 29.6817 |
| 2010's | 35 (27.34) | 24.3611 |
| 2020's | 26 (20.31) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X | 2 |
| Liu, Y | 1 |
| Lin, Z | 2 |
| Wu, B | 2 |
| Nong, G | 1 |
| Chen, Y | 7 |
| Lu, Y | 1 |
| Ji, X | 2 |
| Zhou, X | 2 |
| Suo, B | 2 |
| Chen, Q | 3 |
| Wei, J | 1 |
| Wang, J | 5 |
| Cao, Y | 2 |
| He, W | 1 |
| Li, X | 5 |
| Zhang, J | 3 |
| Rong, C | 1 |
| Yan, C | 1 |
| Chen, J | 2 |
| Yang, W | 2 |
| Yu, L | 1 |
| Dai, H | 1 |
| Shao, Y | 1 |
| Lin, Y | 3 |
| Wang, B | 1 |
| Miao, M | 1 |
| Ye, G | 1 |
| Tang, X | 1 |
| Wang, Z | 1 |
| Shen, Y | 1 |
| Song, X | 1 |
| Benghezal, M | 1 |
| Marshall, BJ | 1 |
| Tang, H | 1 |
| Li, H | 3 |
| Kumar, S | 1 |
| Mehrotra, T | 1 |
| Talukdar, D | 1 |
| Verma, J | 1 |
| Chandra Karmakar, B | 1 |
| Paul, S | 1 |
| Chaudhuri, S | 1 |
| Kumari Pragasam, A | 1 |
| Bakshi, S | 1 |
| Kumari, S | 1 |
| Chawla, M | 1 |
| Purohit, A | 1 |
| Porey Karmakar, S | 1 |
| Mutreja, A | 1 |
| Banerjee, S | 1 |
| Ray, A | 1 |
| Ramamurthy, T | 2 |
| Mukhopadyay, AK | 1 |
| Das, B | 1 |
| Zeng, J | 1 |
| Xie, C | 1 |
| Zhang, L | 1 |
| Liu, X | 3 |
| Chan, MTV | 1 |
| Wu, WKK | 1 |
| Chen, H | 2 |
| Bi, H | 1 |
| Chen, X | 4 |
| Zhao, X | 1 |
| Wang, S | 1 |
| Lyu, T | 1 |
| Han, S | 1 |
| Lin, T | 1 |
| Li, M | 1 |
| Yuan, D | 1 |
| Liu, J | 8 |
| Shi, Y | 2 |
| Shu, X | 4 |
| Ye, D | 1 |
| Hu, C | 1 |
| Peng, K | 1 |
| Zhao, H | 1 |
| Jiang, M | 1 |
| Lu, L | 3 |
| Wang, Y | 5 |
| Ye, J | 5 |
| Han, Y | 3 |
| Lou, G | 4 |
| Li, Y | 10 |
| Yan, H | 3 |
| Du, Q | 5 |
| Huang, J | 2 |
| Hu, S | 1 |
| Zhou, Y | 1 |
| Deng, Y | 2 |
| Bo, Y | 1 |
| Shi, R | 1 |
| Zhao, W | 1 |
| Hou, Z | 1 |
| Hu, J | 2 |
| Zhang, X | 3 |
| Yong, H | 2 |
| Wang, P | 1 |
| Li, F | 1 |
| Qi, H | 1 |
| Wang, X | 3 |
| Jin, L | 1 |
| Cui, T | 1 |
| Yang, B | 1 |
| Yu, Y | 1 |
| Ma, B | 1 |
| Fu, L | 1 |
| Ma, Z | 1 |
| Tang, N | 1 |
| You, Y | 1 |
| Guo, J | 1 |
| Yu, X | 1 |
| Yao, L | 1 |
| Gao, R | 1 |
| Xin, R | 1 |
| Cao, Z | 1 |
| Ma, L | 1 |
| Ma, S | 1 |
| Tang, Y | 1 |
| Hao, Q | 1 |
| Mu, R | 1 |
| Niu, M | 1 |
| Su, X | 1 |
| Gao, H | 1 |
| Hu, L | 1 |
| Zeng, X | 1 |
| Ai, Q | 1 |
| Liu, C | 1 |
| Liu, L | 1 |
| Li, GQ | 1 |
| Bordin, DS | 1 |
| Voynovan, IN | 1 |
| Sarsenbaeva, AS | 1 |
| Zaytsev, OV | 1 |
| Abdulkhakov, RA | 1 |
| Bakulina, NV | 1 |
| Bakulin, IG | 1 |
| Osipenko, MF | 1 |
| Livzan, MA | 1 |
| Alekseenko, SA | 1 |
| Tarasova, LV | 1 |
| Tarasova, GN | 1 |
| Bogomolov, PO | 1 |
| Maev, IV | 2 |
| Andreev, DN | 1 |
| Abdulkhakov, SR | 1 |
| Starostin, BD | 1 |
| Bakanova, NV | 1 |
| Kononova, AG | 1 |
| Kolbasnikov, SV | 1 |
| Bueverova, EL | 1 |
| Moreira, L | 1 |
| Megraud, F | 1 |
| O'Morain, C | 2 |
| Perez Nyssen, O | 1 |
| Gisbert, J | 1 |
| Zheng, X | 2 |
| Wu, Y | 1 |
| Liao, O | 1 |
| Wu, H | 1 |
| Zhang, XD | 1 |
| Zhang, DY | 1 |
| Chen, RX | 1 |
| Chen, SJ | 1 |
| Chen, C | 1 |
| Zeng, F | 1 |
| Huang, SM | 1 |
| Li, D | 1 |
| Bai, FH | 1 |
| Xu, F | 1 |
| Zhang, H | 1 |
| Xiao, H | 1 |
| Meng, J | 1 |
| Pan, J | 2 |
| Shi, Z | 1 |
| Lin, D | 1 |
| Yang, N | 1 |
| Meng, F | 1 |
| Lin, L | 1 |
| Jin, Z | 1 |
| Zhou, Q | 1 |
| Wu, J | 2 |
| Han, C | 1 |
| Lu, WQ | 1 |
| Wang, N | 1 |
| Wu, SR | 1 |
| Wang, YX | 1 |
| Ma, JP | 1 |
| Wang, JH | 1 |
| Hao, C | 1 |
| Yuan, DH | 1 |
| Liu, N | 1 |
| Shi, YQ | 1 |
| Kan, LD | 1 |
| Huang, YT | 1 |
| Qiu, Y | 1 |
| Yu, XL | 1 |
| Fang, HM | 1 |
| Li, LC | 1 |
| Ji, CR | 3 |
| Li, YY | 3 |
| Qiao, C | 3 |
| Qu, JY | 2 |
| Hu, JN | 2 |
| Lin, MJ | 2 |
| Ji, R | 2 |
| Li, LX | 2 |
| Zuo, XL | 2 |
| Li, YQ | 1 |
| Guo, CG | 1 |
| Zhang, Y | 2 |
| Zuo, X | 2 |
| Ji, C | 2 |
| Qu, J | 1 |
| Wan, M | 2 |
| Lin, B | 1 |
| Lin, M | 1 |
| Qi, Q | 1 |
| Kong, S | 1 |
| Huang, K | 1 |
| Jin, D | 1 |
| Zhang, G | 4 |
| Ye, F | 1 |
| Lin, BS | 1 |
| Zha, J | 1 |
| Hu, Y | 1 |
| Zhu, Y | 5 |
| Lu, NH | 3 |
| Mohammadi, M | 1 |
| Attaran, B | 1 |
| Malekzadeh, R | 7 |
| Graham, DY | 4 |
| Zamani, M | 1 |
| Rahbar, A | 1 |
| Shokri-Shirvani, J | 1 |
| Zhuge, L | 1 |
| Wu, S | 1 |
| Zhao, RL | 1 |
| Li, Z | 1 |
| Xie, Y | 5 |
| Chen, L | 1 |
| He, J | 1 |
| Wang, L | 1 |
| Ge, Q | 1 |
| Chu, H | 1 |
| Long, Y | 1 |
| He, H | 1 |
| Li, A | 1 |
| Chen, S | 1 |
| Zhang, Z | 1 |
| Hong, J | 1 |
| Liu, W | 3 |
| Lu, H | 5 |
| Du, Y | 1 |
| Wang, W | 1 |
| Xu, J | 1 |
| Huo, L | 1 |
| Lan, C | 1 |
| Wang, H | 4 |
| Lu, N | 3 |
| Tang, D | 1 |
| Yuan, L | 1 |
| Yue, C | 1 |
| Cai, T | 1 |
| Yao, Y | 1 |
| Wang, F | 3 |
| Zhang, YW | 2 |
| Hu, WL | 1 |
| Cai, Y | 1 |
| Zheng, WF | 1 |
| Kim, JJ | 2 |
| Kao, JY | 1 |
| Dai, N | 1 |
| Si, JM | 1 |
| Yi, DM | 1 |
| Yang, TT | 1 |
| Chao, SH | 1 |
| Li, YX | 1 |
| Zhou, YL | 1 |
| Zhang, HH | 1 |
| Lan, L | 1 |
| Wang, XM | 2 |
| Zhang, YR | 1 |
| Li, J | 1 |
| Ding, SZ | 1 |
| Miftahussurur, M | 1 |
| Aftab, H | 1 |
| Shrestha, PK | 1 |
| Sharma, RP | 1 |
| Subsomwong, P | 1 |
| Waskito, LA | 1 |
| Doohan, D | 1 |
| Fauzia, KA | 1 |
| Yamaoka, Y | 1 |
| Song, C | 1 |
| Qian, X | 1 |
| Song, Y | 1 |
| Xiong, Z | 1 |
| Yu, T | 1 |
| Ding, L | 1 |
| Jin, Y | 1 |
| Zhang, S | 1 |
| Yue, M | 1 |
| Yao, D | 1 |
| Wang, Q | 1 |
| Ogata, SK | 2 |
| Godoy, AP | 1 |
| da Silva Patricio, FR | 1 |
| Kawakami, E | 2 |
| Ma, HJ | 1 |
| Wang, JL | 1 |
| Navarro-Rodriguez, T | 2 |
| Silva, FM | 4 |
| Barbuti, RC | 4 |
| Mattar, R | 1 |
| Moraes-Filho, JP | 1 |
| de Oliveira, MN | 1 |
| Bogsan, CS | 1 |
| Chinzon, D | 1 |
| Eisig, JN | 4 |
| Zheng, XL | 1 |
| Xu, L | 1 |
| Cheng, H | 3 |
| Gao, W | 3 |
| Dong, X | 1 |
| Hu, F | 2 |
| Lü, Z | 1 |
| Zhou, H | 2 |
| Liu, Z | 1 |
| Zhu, X | 2 |
| He, X | 1 |
| Liu, D | 1 |
| Ma, J | 1 |
| Lu, ZF | 1 |
| Yang, Z | 1 |
| Guo, XB | 1 |
| Fan, HZ | 1 |
| Tang, JH | 1 |
| Zeng, XP | 1 |
| Wen, JB | 1 |
| Li, XQ | 1 |
| He, XX | 1 |
| Ma, JH | 1 |
| Liu, DS | 1 |
| Huang, CB | 1 |
| Xu, NJ | 1 |
| Wang, NR | 1 |
| Hajaghamohammadi, A | 1 |
| Safiabadi Tali, SH | 1 |
| Samimi, R | 1 |
| Oveisi, S | 1 |
| Kazemifar, AM | 1 |
| Zhang, F | 1 |
| Bao, ZJ | 1 |
| Shi, DM | 1 |
| Xiang, P | 1 |
| Xiao, L | 2 |
| Huang, YQ | 1 |
| Zhang, GS | 1 |
| Yin, SM | 1 |
| Meng, X | 1 |
| Liu, G | 1 |
| Kong, C | 1 |
| Zhao, L | 1 |
| Yang, L | 1 |
| Farahmand, F | 1 |
| Mohammadi, T | 1 |
| Najafi, M | 1 |
| Fallahi, G | 1 |
| Khodadad, A | 1 |
| Motamed, F | 1 |
| Mahdi Marashi, S | 1 |
| Shoaran, M | 1 |
| Nabavizadeh Rafsanjani, R | 1 |
| Felga, GE | 1 |
| Zaterka, S | 2 |
| Abbas, Z | 1 |
| Yakoob, J | 1 |
| Abid, S | 1 |
| Jafri, W | 1 |
| Islam, M | 1 |
| Azam, Z | 1 |
| Hilal, I | 1 |
| Wang, XY | 2 |
| Shen, SR | 3 |
| Sanches, B | 1 |
| Coelho, L | 1 |
| Moretzsohn, L | 1 |
| Vieira, G | 1 |
| De Francesco, V | 1 |
| Ierardi, E | 2 |
| Hassan, C | 2 |
| Zullo, A | 2 |
| Hu, FL | 2 |
| De Francesco, V | 1 |
| Rodriguez, TN | 2 |
| Malfertheiner, P | 2 |
| Moraes Filho, JP | 1 |
| Nizhevich, AA | 2 |
| Shcherbakov, PL | 3 |
| Akhmadeeva, EN | 2 |
| Siavoshi, F | 3 |
| Saniee, P | 1 |
| Latifi-Navid, S | 1 |
| Massarrat, S | 7 |
| Sheykholeslami, A | 1 |
| Xu, C | 1 |
| Zou, H | 1 |
| Riahizadeh, S | 1 |
| Agah, S | 2 |
| Zendehdel, N | 2 |
| Sotoudehmanesh, R | 3 |
| Ebrahimi-Dariani, N | 3 |
| Pourshams, A | 2 |
| Vahedi, H | 4 |
| Mikaeli, J | 2 |
| Khatibian, M | 3 |
| Ghadir, MR | 1 |
| Shafaghi, A | 1 |
| Iranikhah, A | 1 |
| Pakdin, A | 1 |
| Joukar, F | 1 |
| Mansour-Ghanaei, F | 2 |
| Khasanov, RSh | 2 |
| Gu, LY | 1 |
| Lin, WW | 1 |
| Chen, XY | 1 |
| Ge, ZZ | 1 |
| Li, XB | 1 |
| Fakheri, H | 4 |
| Taghvaei, T | 1 |
| Hosseini, V | 2 |
| Bari, Z | 2 |
| Saha, SK | 2 |
| Masud, H | 1 |
| Islam, N | 1 |
| Raihan, AS | 1 |
| Roy, PK | 1 |
| Hasan, M | 1 |
| Sardarian, H | 1 |
| Isakov, V | 1 |
| Domareva, I | 1 |
| Koudryavtseva, L | 1 |
| Maev, I | 1 |
| Ganskaya, Z | 1 |
| Treiber, G | 1 |
| Ammon, S | 1 |
| Klotz, U | 1 |
| Queiroz, DM | 5 |
| Dani, R | 2 |
| Silva, LD | 1 |
| Santos, A | 1 |
| Moreira, LS | 2 |
| Rocha, GA | 5 |
| Corrêa, PR | 1 |
| Reis, LF | 1 |
| Nogueira, AM | 1 |
| Alvares Cabral, MM | 1 |
| Esteves, AM | 1 |
| Tanure, J | 1 |
| Vasil'ev, IuV | 1 |
| Zvenigorodskaia, LA | 1 |
| Coelho, LG | 7 |
| Martins, GM | 2 |
| Passos, MC | 7 |
| Bueno, ML | 2 |
| Sanches, BS | 1 |
| Lopes, LG | 2 |
| Miranda, CH | 1 |
| Castro, LP | 5 |
| Roghani, HS | 1 |
| Shirekhoda, M | 1 |
| Butorab, Z | 1 |
| Mirmomen, S | 1 |
| Noormohammadpoor, P | 1 |
| Sotodehmanesh, R | 1 |
| Haghpanah, B | 1 |
| Bahrami, H | 1 |
| Merat, S | 2 |
| Guo, CY | 1 |
| Wu, YB | 1 |
| Liu, HL | 1 |
| Wu, JY | 1 |
| Zhong, MZ | 1 |
| Qasim, A | 1 |
| Sebastian, S | 1 |
| Thornton, O | 1 |
| Dobson, M | 1 |
| McLoughlin, R | 1 |
| Buckley, M | 1 |
| O'Connor, H | 1 |
| Candelli, M | 1 |
| Nista, EC | 1 |
| Carloni, E | 1 |
| Pignataro, G | 1 |
| Zocco, MA | 1 |
| Cazzato, A | 1 |
| Di Campli, C | 1 |
| Fini, L | 1 |
| Gasbarrini, G | 1 |
| Gasbarrini, A | 1 |
| Gadzhieva, MG | 1 |
| Moretzsohn, LD | 1 |
| Vieira, WL | 1 |
| Gallo, MA | 1 |
| Cindr, JM | 1 |
| Cerqueira, MC | 1 |
| Vitiello, L | 1 |
| Ribeiro, ML | 1 |
| Mendonça, S | 1 |
| Pedrazzoli-Júnior, J | 1 |
| Amini, M | 1 |
| Khedmat, H | 1 |
| Yari, F | 1 |
| Karateev, AE | 1 |
| Nasonov, EL | 1 |
| Radenska-Lopovok, SG | 1 |
| Datta, S | 1 |
| Chattopadhyay, S | 1 |
| Patra, R | 1 |
| De, R | 1 |
| Hembram, J | 1 |
| Chowdhury, A | 1 |
| Bhattacharya, SK | 1 |
| Berg, DE | 1 |
| Nair, GB | 1 |
| Mukhopadhyay, AK | 1 |
| McLoughlin, RM | 1 |
| O'Morain, CA | 1 |
| O'Connor, HJ | 1 |
| Jia, Y | 1 |
| Xu, CX | 2 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Nijevitch, AA | 1 |
| Sataev, VU | 1 |
| Al Khashash, R | 1 |
| Tuygunov, MM | 1 |
| Gisbert, JP | 1 |
| Hashimoto, CL | 1 |
| Cianci, R | 1 |
| Montalto, M | 1 |
| Pandolfi, F | 1 |
| Gasbarrini, GB | 1 |
| Cammarota, G | 1 |
| Huo, XH | 1 |
| Chu, JK | 1 |
| Yang, XF | 1 |
| Zhang, LJ | 1 |
| Ma, JC | 1 |
| Yu, J | 1 |
| Su, Z | 1 |
| Xu, H | 1 |
| Zhang, C | 1 |
| Shao, S | 1 |
| Li, L | 1 |
| Qiu, G | 1 |
| Machado, RS | 1 |
| Langner, M | 1 |
| Fukushima, E | 1 |
| Carelli, AP | 1 |
| Bonucci, VC | 1 |
| Patricio, FR | 1 |
| Safari, F | 1 |
| Doratotaj, D | 1 |
| Khatami, GR | 1 |
| Fallahi, GH | 1 |
| Mirnaseri, MM | 1 |
| Ajvadi, Y | 1 |
| Nasseri-Moghaddam, S | 1 |
| Ali-Asgari, A | 1 |
| Tovey, FI | 1 |
| Zhou, JD | 1 |
| Daghaghzadeh, H | 1 |
| Emami, MH | 1 |
| Karimi, S | 1 |
| Raeisi, M | 1 |
| Buzás, GM | 1 |
| Józan, J | 1 |
| Moura, SB | 2 |
| Mendes, EN | 3 |
| Barbosa, AJ | 2 |
| de Carvalho, AS | 1 |
| Long, DS | 1 |
| Li, CM | 1 |
| Yang, QG | 1 |
| Resende, LM | 2 |
| Oliveira, CA | 2 |
| Lima Júnior, GF | 2 |
| Cunha-Melo, JR | 1 |
| Dobrilla, G | 2 |
| Piazzi, L | 2 |
| Amplatz, S | 2 |
| Segura, AM | 1 |
| Gutiérrez, O | 1 |
| Otero, W | 1 |
| Angel, A | 1 |
| Genta, RM | 1 |
| Van Zwet, AA | 1 |
| Thijs, JC | 1 |
| van der Wouden, EJ | 1 |
| Kooy, A | 1 |
| Ramirez-Ramos, A | 1 |
| Gilman, RH | 1 |
| Leon-Barua, R | 1 |
| Recavarren-Arce, S | 1 |
| Watanabe, J | 1 |
| Salazar, G | 1 |
| Checkley, W | 1 |
| McDonald, J | 1 |
| Valdez, Y | 1 |
| Cordero, L | 1 |
| Carrazco, J | 1 |
| Lü, B | 1 |
| Xiao, S | 1 |
| Xiao, SD | 6 |
| Liu, WZ | 4 |
| Hu, PJ | 3 |
| Xia, DH | 2 |
| Tytgat, GN | 3 |
| Wu, SM | 1 |
| Zhang, DZ | 2 |
| Xu, WW | 2 |
| Dong, Q | 1 |
| Dias, MG | 1 |
| Franco, JM | 1 |
| Magalhães, LC | 1 |
| Mendes, GS | 1 |
| De Castro, LP | 1 |
| Toppa, NH | 1 |
| Cabral, MM | 1 |
| Salles, PG | 1 |
| Osato, MS | 2 |
| Hoffman, J | 1 |
| Opekun, AR | 1 |
| Anderson, SY | 1 |
| El-Zimaity, HM | 1 |
| Gomes, BS | 1 |
| Ansari, R | 1 |
| Alizadeh, BZ | 2 |
| Eshraghian, MR | 1 |
| Vakili, A | 1 |
| Saghari, M | 1 |
| Cui, Y | 1 |
| Kwon, DH | 1 |
| Lee, M | 1 |
| Kim, JG | 1 |
| El-Zaatari, FA | 1 |
| Fazel, A | 1 |
| Calafatti, SA | 1 |
| Ortiz, RA | 1 |
| Deguer, M | 1 |
| Martinez, M | 1 |
| Pedrazzoli, J | 1 |
| Li, ZS | 1 |
| Lu, XH | 1 |
| Fang, XC | 1 |
| Dariani, NE | 1 |
| Asgari, AA | 1 |
| Wong, WM | 1 |
| Wong, BC | 1 |
| Gu, Q | 1 |
| Yin, Y | 1 |
| Wang, WH | 1 |
| Fung, FM | 1 |
| Lai, KC | 1 |
| Xia, HH | 1 |
| Lam, SK | 1 |
| Chausson, Y | 2 |
| Costa, EL | 1 |
| Maia, AF | 1 |
| Brandao, MJ | 1 |
| Rodrigues, DC | 1 |
| Benvenuti, S | 1 |
| Di Fede, F | 1 |
| Castro, Lde P | 1 |
| Jiang, SJ | 1 |
| Wang, RN | 1 |
| Zhang, ZH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy[NCT04678492] | Phase 4 | 658 participants (Actual) | Interventional | 2020-12-20 | Completed | ||
| Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888] | Phase 4 | 260 participants (Anticipated) | Interventional | 2023-03-12 | Recruiting | ||
| Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy[NCT03609892] | Phase 4 | 658 participants (Actual) | Interventional | 2018-08-01 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-07-31 | Not yet recruiting | ||
| Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-06-25 | Recruiting | ||
| Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori : A Multicenter Randomized Non-Inferiority Trial[NCT05997433] | 254 participants (Anticipated) | Interventional | 2023-09-02 | Recruiting | |||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT05049902] | Phase 4 | 1,300 participants (Actual) | Interventional | 2021-09-21 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT04901117] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2021-06-30 | Not yet recruiting | ||
| Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study[NCT03658733] | Phase 4 | 120 participants (Anticipated) | Interventional | 2018-12-15 | Not yet recruiting | ||
| Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy[NCT02894268] | Phase 4 | 300 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| Quadruple Therapy Using Esomeprazole, Colloidal Bismuth Subcitrate, Amoxicillin-Clavulanate, and Furazolidone in Patients Who Failed to Eradicate H. Pylori With Triple Therapy[NCT00520949] | 176 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for furazolidone and Infections, Helicobacter
| Article | Year |
|---|---|
Host Cell Antimicrobial Responses against
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2022 |
Delayed-type allergic reaction to furazolidone: A case report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Dermatitis, Allergic Contact; Drug Hypersensitivity; Furazolidone; Hel | 2023 |
Safety of furazolidone-containing regimen in
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacte | 2020 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2017 |
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Topics: Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Furazolidone; H | 2017 |
Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Treatment | 2018 |
Treatment of H. pylori infection: a review.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Clarithromycin; Fluoroquinolones; Furazolidone | 2005 |
Eradication of Helicobacter pylori: recent advances in treatment.
Topics: Drug Resistance, Bacterial; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levo | 2005 |
Third-line rescue therapy for Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Doxycycline; Furazolidone; Helicobacter Infections; Helicobacter pylori; Huma | 2006 |
Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.
Topics: Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Furazolidone; H | 2007 |
[Helicobacter pylori and the treatment of gastric ulcer. Reflections and uncertainties].
Topics: Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Furazolidone; Helicobacter Infections | 1993 |
Helicobacter pylori and gastric ulcer therapy: reflections and uncertainties.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cefixime; Cefotaxime; Cimetidine; Drug Therapy, Combinatio | 1992 |
65 trials available for furazolidone and Infections, Helicobacter
| Article | Year |
|---|---|
Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazol | 2021 |
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; | 2022 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; | 2023 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; | 2023 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; | 2023 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infec | 2023 |
Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bismuth; Furazolidone; Helicobacter Infections | 2023 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resist | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Berberine; Drug Therapy, Combination; Female; Furazolidon | 2020 |
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Co | 2020 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Fu | 2021 |
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Topics: Adult; Amoxicillin; Bismuth; Breath Tests; China; Drug Administration Schedule; Drug Therapy, Combin | 2018 |
Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; China; Esomeprazole; Female; Furazolido | 2018 |
Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Resistance, Bacterial; Dru | 2019 |
Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy | 2019 |
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Brazil; Disease Eradication; Double- | 2013 |
[Efficacy of furazolidone-based quadruple therapy as rescue treatment for refractory Helicobacter pylori infection].
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Furazolidone; Helicobacter In | 2013 |
[Efficacy of triple versus quadruple furazolidone-based eradication regimens for Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Furazolidone; Hel | 2014 |
Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combin | 2014 |
Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Breath T | 2014 |
Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 2016 |
Comparison of Ciprofloxacin-Based Triple Therapy with Conventional Triple Regimen for Helicobacter pylori Eradication in Children.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Dose-Response Relationship, Drug; Drug The | 2016 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
[Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2008 |
Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2008 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Dose-Response Relations | 2009 |
[Rifaksimin in complex treatment of Helicobacter pylori infection in children (a pilot study)].
Topics: Adolescent; Anti-Infective Agents; Breath Tests; Child; Drug Therapy, Combination; Female; Furazolid | 2009 |
[Effect of birid triple viable on peptic ulcer patients with Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug The | 2010 |
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Meth | 2010 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents | 2011 |
[Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; D | 2011 |
Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2011 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarith | 2012 |
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2012 |
Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therap | 2002 |
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; | 2002 |
[Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 2002 |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Ag | 2003 |
Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug The | 2003 |
The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Breath Tests; Drug Resistance, Bacterial | 2003 |
Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, C | 2004 |
Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulce | 2004 |
Eradication rate of Helicobacter pylori in dyspeptic patients.
Topics: Analysis of Variance; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Drug Therapy, Combination; | 2005 |
[Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
Topics: Aged; Anti-Infective Agents, Local; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arth | 2005 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.
Topics: Adolescent; Amoxicillin; Antacids; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Female; | 2005 |
Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; As | 2006 |
Furazolidone-based triple therapy for H pylori gastritis in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2006 |
Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Drug Therapy, Combination; | 2007 |
One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fe | 2007 |
[Clinical observation on verrucous gastritis with combined therapy of traditional Chinese and Western medicine].
Topics: Adolescent; Adult; Chronic Disease; Cimetidine; Drug Therapy, Combination; Drugs, Chinese Herbal; Fe | 1994 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow- | 1997 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Cla | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, C | 1999 |
Furazolidone combination therapies for Helicobacter pylori infection in the United States.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fu | 2000 |
Once-daily Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Dose-Response Rel | 2000 |
Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Drug Combinations; Duodenal Ulcer; Female; Furazolidone; Helicobacter | 2000 |
A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Therapy, C | 2000 |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithr | 2001 |
Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biological Availability; Cros | 2001 |
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulce | 2001 |
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Resistance, Multiple | 2002 |
Helicobacter pylori and gastric ulcer therapy: reflections and uncertainties.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cefixime; Cefotaxime; Cimetidine; Drug Therapy, Combinatio | 1992 |
The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Female; Furazolidone; Gastric Mucosa; | 1990 |
52 other studies available for furazolidone and Infections, Helicobacter
| Article | Year |
|---|---|
Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Dose-Response Re | 2021 |
Risk factors of furazolidone-associated fever.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Case-Control Studies; Clarithromycin; Drug Therapy, Combi | 2022 |
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomy | 2022 |
Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Female; Furaz | 2022 |
Region-specific genomic signatures of multidrug-resistant Helicobacter pylori isolated from East and South India.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2022 |
Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Furazolidone; | 2022 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter I | 2023 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter I | 2023 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter I | 2023 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter I | 2023 |
Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistanc | 2023 |
Long-Read- and Short-Read-Based Whole-Genome Sequencing Reveals the Antibiotic Resistance Pattern of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Microbial; Furaz | 2023 |
[Effectiveness of empirical
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Furazolidone; Helicobacter Inf | 2023 |
Antibiotic resistance profile of
Topics: Amoxicillin; Anti-Bacterial Agents; Cefixime; Clarithromycin; Doxycycline; Drug Resistance, Bacteria | 2023 |
Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Drug Costs; Drug Therapy, C | 2020 |
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report.
Topics: Anti-Bacterial Agents; Bismuth; DNA, Bacterial; Drug Hypersensitivity; Drug Resistance, Bacterial; D | 2021 |
Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance | 2021 |
Resistance of
Topics: Asia; Drug Resistance, Bacterial; Europe; Furazolidone; Helicobacter Infections; Helicobacter pylori | 2017 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone | 2018 |
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Topics: Adult; Alcohol Drinking; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2018 |
Effective therapeutic regimens in two South Asian countries with high resistance to major
Topics: Anti-Bacterial Agents; Bangladesh; DNA Gyrase; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Re | 2019 |
Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice.
Topics: Adult; Aged; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middl | 2019 |
High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Brazil; Child; Child, Preschool; Clarithromyc | 2013 |
Quadruple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Chi-Square Distribution; Drug Therapy | 2013 |
[Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Furazolidone; Helicoba | 2014 |
Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; F | 2014 |
[Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province].
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Resistance, Microbial; Furazolidone | 2016 |
Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Drug Therapy, Com | 2009 |
Is furazolidone therapy for Helicobacter pylori effective and safe?
Topics: Anti-Infective Agents; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans | 2009 |
Furazolidone therapy for Helicobacter pylori: is it effective and safe?
Topics: Animals; Anti-Infective Agents, Local; Drug-Related Side Effects and Adverse Reactions; Furazolidone | 2009 |
Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Chi-Square Distribution; Clari | 2010 |
[Rifaximin in combined treatment of the Helicobacter pylori infection in childhood].
Topics: Adolescent; Anti-Infective Agents; Child; Drug Therapy, Combination; Female; Furazolidone; Helicobac | 2011 |
To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bangladesh; Drug Therapy, | 2011 |
[Application of furazolidone-based regimens for Helicobacter pylori eradication].
Topics: Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans | 2012 |
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2002 |
Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Fem | 2005 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2005 |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Furazol | 2005 |
How effective are rescue H. pylori eradication therapies in patients with dyspepsia?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Drug Therapy, Combination | 2005 |
A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Local; Chi-Square Distribution; Cohort Studies; Conf | 2005 |
Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Furazolidone; Gastritis; Gen | 2006 |
Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Child; Child, Preschool; Clarithromycin | 2006 |
Treatment of duodenal ulceration with Furazolidine in China preceded the discovery of its association with H pylori.
Topics: Anti-Infective Agents, Local; China; Duodenal Ulcer; Duodenum; Furazolidone; Helicobacter Infections | 2007 |
[Antibiotic resistance of Helicobacter pylori].
Topics: Anti-Bacterial Agents; Clarithromycin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Bacteria | 2007 |
Effect of Helicobacter pylori eradication on G-cell and D-cell density in children.
Topics: Adolescent; Amoxicillin; Cell Count; Child; Drug Therapy, Combination; Female; Furazolidone; Gastrin | 1994 |
Histology of the mucosa of gastric antrum and body before and after eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Gastric Mucosa; | 1993 |
Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Gastric Mucosa; | 1993 |
Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combinati | 1997 |
Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Fur | 1997 |
[Effect of Helicobacter pylori on gastric epithelial apoptosis].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Apoptosis; Drug Therapy, Combination; Epithel | 1997 |
Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.
Topics: Anti-Infective Agents, Urinary; Antitrichomonal Agents; Drug Resistance, Microbial; Furazolidone; Ge | 2001 |
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Drug Therapy, Combination; | 2001 |
Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study.
Topics: Amoxicillin; Brazil; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; | 1992 |
Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse.
Topics: Adult; Amoxicillin; Breath Tests; Carbon Radioisotopes; Drug Administration Schedule; Drug Therapy, | 1991 |